The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. PREVENT is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.
Read more About PREVENT.
Submission deadlines occur twice per year on the second Monday in January and July.
New! NEXT Deadline: January 11, 2021
101 Projects from PREVENT Cycles 1 through 17:
- 61 chemoprevention projects
- 32 immunoprevention projects
- 8 biomarker projects
Read more about supported projects and supported prevention approaches.
- Efficacy and Intermediate Endpoint Biomarker Work
- Toxicology and Pharmacology Testing
- CGMP Production of Vaccines and Biologicals
- Prime Contractors 2019–2023
- Governance Structure
- Technology Transfer Considerations
PREVENT and DCP-funded Early Phase Clinical Projects’ Results Presented at AACR Virtual Annual Meetings 2020 I & II
NCI participated in the American Association for Cancer Research (AACR) Annual Meetings 2020, held virtually on April 27 - 28, 2020 (Meeting I) and June 22 - 24, 2020 (Meeting II), including presenting the following research results from PREVENT and Early Phase Clinical Projects.
PREVENT and Consortia Project Results Presented at the AACR Annual Meeting 2019
NCI participated in the American Association for Cancer Research (AACR) Annual Meeting held March 29 - April 3, 2019 at Georgia World Congress Center in Atlanta, GA, including the presentation of research results from the latest PREVENT- and Consortia-supported projects.